Korean J Hematol.  2012 Mar;47(1):3-5. 10.5045/kjh.2012.47.1.3.

Allogeneic stem cell transplantation for neuroblastoma

• Sung KW

• KMID: 2251963
• DOI: http://doi.org/10.5045/kjh.2012.47.1.3

Abstract

No abstract available.

MeSH Terms

Neuroblastoma
Stem Cell Transplantation
Stem Cells

Figure

• 

  Fig. 1 Representative case. The patient had 131I-meta-iodobenzylguanidine (MIBG) uptake at relapse after tandem HDCT/auto-SCT (A) (arrow head). He still had MIBG uptake arrows after conventional salvage treatment (B) (arrow head). RI alloSCT was given after high-dose 131I-MIBG treatment (18 mCi/kg). Regimen-related toxicity was minimal and rapid engraftment and complete donor chimerism were successfully achieved. Grade I acute graft-versus-host disease (GVHD) developed after withdrawal of immune suppression, and he had a moderate chronic GVHD. MIBG uptake was absent from day 90 and day 180 evaluations (C and D).

Reference

1. Inoue M, Nakano T, Yoneda A, et al. Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation. Bone Marrow Transplant. 2003. 32:103–106.

2. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood. 2004. 103:435–441.

3. Takahashi H, Manabe A, Aoyama C, et al. Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma. Pediatr Blood Cancer. 2008. 50:676–678.

4. Toporski J, Garkavij M, Tennvall J, et al. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol Blood Marrow Transplant. 2009. 15:1077–1085.

5. Pérez-Martínez A, Leung W, Muñoz E, et al. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. Pediatr Blood Cancer. 2009. 53:120–124.

6. Jubert C, Wall DA, Grimley M, Champagne MA, Duval M. Engraftment of unrelated cord blood after reduced-intensity conditioning regimen in children with refractory neuroblastoma: a feasibility trial. Bone Marrow Transplant. 2011. 46:232–237.

7. Sung KW, Park JE, Chueh HW, et al. Reduced-intensity allogeneic stem cell transplantation for children with neuroblastoma who failed tandem autologous stem cell transplantation. Pediatr Blood Cancer. 2011. 57:660–665.

8. Lang P, Pfeiffer M, Müller I, et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr. 2006. 218:321–326.

9. Goi K, Inukai T, Honna H, et al. Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN. Bone Marrow Transplant. 2011. 46:835–839.